Abstract: The present invention relates to a glycine transporter-1 inhibitor having the formula (I) wherein X is 1-3 substituents selected from H, halogen, methyl, methoxy, trifluoromethyl and trifluoromethoxy and Y is 1-3 substituents selected from H, methyl and halogen or a pharmaceutically acceptable salt thereof for use in a treatment in humans to suppress the level of one or more hormone selected from luteinizing hormone, follicle-stimulating hormone, estradiol and testosterone. The present invention further relates to such a glycine transporter-1 inhibitor as part of a contraceptive regimen or as a treatment for hypersexuality.

Abstract: The present invention relates to a method and kits for treating bipolar disorder in a mammal, including a human, the treatments including treatment of bipolar disorder including rapid-cycling, treatment of symptoms of bipolar disorder including acute mania or hypomania and depression, and episodes or occurrences including both acute mania or hypomania and depression; treatment for effecting mood stabilization; treatment for preventing relapse into bipolar episodes, and for the treatment of suicidal thoughts and tendencies associated with bipolar disorder, comprising administering to said mammal an effective amount of a compound of Formula or a pharmaceutically acceptable salt, solvate, hydrate or optical isomer thereof.

Abstract: The present invention relates to a method and kits for treating bipolar disorder in a mammal, including a human, the treatments including treatment of bipolar disorder including rapid-cycling, treatment of symptoms of bipolar disorder including acute mania or hypomania and depression, and episodes or occurrences including both acute mania or hypomania and depression; treatment for effecting mood stabilization; treatment for preventing relapse into bipolar episodes, and for the treatment of suicidal thoughts and tendencies associated with bipolar disorder, comprising administering to said mammal an effective amount of a compound of Formula or a pharmaceutically acceptable salt, solvate, hydrate or optical isomer thereof.

Abstract: The present invention is concerned with compounds having 5-HT1A antagonistic activity useful in treating CNS disorders and having formula 2 ##STR1## wherein R.sub.1 is halogen, lower alkyl or alkoxy, hydroxy, trifluotomethyl or cyano,m has the value 1 or 2 and n has the value 0 or 1,A represents an alkylene chain containing 2-6 C-atoms which may be substituted with one or more lower alkyl groups or a monocyclic (hetero)aryl group, andB is methylene, ethylene, carbonyl, sulfinyl, sulfonyl or sulfur, and salts thereof.